Vir Biotechnology (VIR)
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
📈 **POSITIVE** • Medium confidence analysis (76%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business